A Phase 1/2 Study of FPA008, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)

Trial Profile

A Phase 1/2 Study of FPA008, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Cabiralizumab (Primary)
  • Indications Pigmented villonodular synovitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Five Prime Therapeutics
  • Most Recent Events

    • 19 Oct 2017 Planned number of patients changed from 45 to 75.
    • 08 Aug 2017 According to a Five Prime Therapeutics media release, the company plans to enroll additional patients in the Phase 2 portion of the trial to refine the dosing schedule to optimize the therapeutic index of cabiralizumab in this chronic disease setting. These additional data are intended to support a pivotal trial for cabiralizumab in PVNS.
    • 04 Jun 2017 Results from this trial published in a Five Prime Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top